Tivic Health teams with strategy firm FSI for ncVNS commercial strategy

Tivic Health Systems announced it has partnered with Fletcher Spaght FSI, a healthcare growth strategy firm, to accelerate development of its commercial strategy for non-invasive cervical vagus nerve stimulation or ncVNS . ..FSI Partner, Bill Sigona, stated, “FSI excels at projects like this, where our insights help clients like Tivic grow while improving patient healthcare. Bringing innovative technologies like ncVNS to market drives us, and we’re excited to support Tivic’s journey in advancing care across multiple therapeutic areas.” The firm has begun a comprehensive market assessment of Tivic Health’s ncVNS technology drawing from clinical outcomes from Tivic Health’s Phase 1 trial. Fletcher Spaght initially identified approximately 30 potential medical use cases for Tivic Health’s ncVNS technology in neurologic, cardiac, psychiatric and autonomic nervous system diseases. The firm is now working closely with Tivic Health’s scientific and clinical leadership to identify the strongest market entry point by interviewing clinical key opinion leaders, patients and payers.